IP Library Granted Patent US 10,041,073
Granted Patent B2
US 10,041,073 · App. 13/069,780 · Granted Aug 7, 2018

Reduced size self-delivering RNAi compounds

Inventors: Anastasia Khvorova (Westborough, MA); William Salomon (Worcester, MA); Joanne Kamens (Newton, MA); Dmitry Samarsky (Westborough, MA); Tod M. Woolf (Sudbury, MA); James Cardia (Franklin, MA)
Assignee: RXi Pharmaceuticals Corporation
C12N15/1136C12N15/111C12N15/113C12N15/1137C12N2310/14C12N2310/315C12N2310/321C12N2310/322C12N2310/3231C12N2310/3341C12N2310/3515C12N2310/3519C12N2320/32C12N2320/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,041,073
App. No.
13/069,780
Granted
Aug 7, 2018
Kind
B2
Abstract

The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.

Claims (27)

1. An isolated nucleic acid molecule comprising

a guide strand of 18-23 nucleotides in length that has complementarity to a miRNA sequence, and

a passenger strand of 8-16 nucleotides in length,

wherein the guide strand and the passenger strand form the nucleic acid molecule such that the nucleic acid molecule has a double stranded region of 10-15 nucleotides in length and a single stranded region, wherein the single stranded region is at the 3′ end of the guide strand and is 2-13 nucleotides in length and comprises at least two phosphorothioate modifications, wherein at least 50% of the pyrimidines in the nucleic acid molecule are modified, and wherein the isolated nucleic acid molecule modulates miRNA-mediated gene expression in a mammalian cell.

2. The nucleic acid molecule of claim 1 , wherein the nucleotide in position one of the guide strand has a 2′-O-methyl modification.

3. The nucleic acid molecule of claim 2 , wherein at least 60%, at least 80%, at least 90% or wherein 100% of the pyrimidines in the nucleic acid molecule are modified.

4. The nucleic acid molecule of claim 2 , wherein modified pyrimidines are 2′fluoro or 2′O methyl modified.

5. The nucleic acid molecule of claim 2 , wherein at least one U or C includes a hydrophobic modification.

6. The nucleic acid molecule of claim 5 , wherein the hydrophobic modification is a methyl or ethyl hydrophobic base modification.

7. The nucleic acid molecule of claim 2 , wherein the guide strand contains 6-8 phosphorothioate modifications.

8. The nucleic acid molecule of claim 2 , wherein the guide strand includes 4-14 phosphate modifications.

9. The nucleic acid molecule of claim 2 , wherein the single stranded region of the guide strand is 6 nucleotides long or 8 nucleotides long.

10. The nucleic acid molecule of claim 2 , wherein the double stranded region is 13 nucleotides long.

11. The nucleic acid molecule of claim 2 , wherein the double stranded nucleic acid molecule has one end that is blunt or includes a one nucleotide overhang.

12. The nucleic acid molecule of claim 2 , wherein the passenger strand is linked at the 3′ end to a sterol.

13. The nucleic acid molecule of claim 2 , wherein the isolated double stranded nucleic acid molecule is an miRNA mimic and wherein the miRNA sequence to which the guide strand is complementary is a miRNA recognition element.

14. The nucleic acid molecule of claim 2 , wherein the isolated double stranded nucleic acid molecule is an miRNA inhibitor and wherein the miRNA sequence to which the guide strand is complementary is an antisense strand of a mature miRNA.

15. The nucleic acid molecule of claim 14 , wherein the guide strand is at least 50% chemically modified.

16. The nucleic acid molecule of claim 14 , wherein the mature miRNA is miR 17-92.

17. A method for modulating miRNA-mediated gene expression in a mammalian cell, comprising contacting the mammalian cell with an isolated double stranded nucleic acid molecule of claim 1 in an effective amount to modulate miRNA-mediated gene expression.

18. The method of claim 17 , wherein the mammalian cell is contacted with the isolated nucleic acid in vivo or ex vivo.

19. A method for modulating miRNA-mediated gene expression in a stem cell, comprising contacting the stem cell with an isolated double stranded nucleic acid molecule of claim 1 in an effective amount to modulate miRNA-mediated gene expression in the stem cell.

20. The nucleic acid molecule of claim 2 , wherein the 2′-O-methyl modification is a 5P-2′O-methyl U modification.

21. The nucleic acid molecule of claim 2 , wherein a plurality of U's and/or C's include a hydrophobic modification.

22. The nucleic acid molecule of claim 2 , wherein the 3′ terminal 10 nucleotides of the guide strand include at least eight phosphorothioate modifications.

23. The nucleic acid molecule of claim 12 , wherein the sterol is cholesterol.

24. The nucleic acid molecule of claim 13 , wherein the miRNA mimic is a mimic of a miRNA selected from the group consisting of miR21, miR 139, miR 7, miR29, miR 122, miR 302-367 cluster, miR 221, miR-96, miR 126, miR 225 and miR 206.

Assignments (6)
CHANGE OF NAME Recorded Dec 7, 2018
From: RXI PHARMACEUTICALS CORPORATION
To: PHIO PHARMACEUTICALS CORP.
Reel/Frame 048380/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2013
From: KHVOROVA, ANASTASIA; SALOMON, WILLIAM; KAMENS, JOANNE; SAMARSKY, DMITRY; WOOLF, TOD M.; CARDIA, JAMES
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 030643/0001 →
RELEASE OF SECURITY INTEREST Recorded May 2, 2012
From: TANG CAPITAL PARTNERS, LP
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 028144/0110 →
CHANGE OF NAME Recorded Sep 29, 2011
From: RNCS, INC.
To: RXI PHARMACEUTICALS CORPORATION
Reel/Frame 026988/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2011
From: RXI PHARMACEUTICALS CORPORATION
To: RNCS, INC.
Reel/Frame 026969/0660 →
SECURITY AGREEMENT Recorded Sep 26, 2011
From: RNCS, INC.
To: TANG CAPITAL PARTNERS, LP
Reel/Frame 026976/0187 →
Continuity (5)
Continuation In Part 13120342
Provisional Application 61192954 · Sep 22, 2008
Provisional Application 61149946 · Feb 4, 2009
Provisional Application 61224031 · Jul 8, 2009
Related Publication 20110263680A1 · Oct 27, 2011
Cited By (1)
US 12,544,344